Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC TranscriptSeeking Alpha • 01/28/26
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRCGlobeNewsWire • 01/27/26
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical DevelopmentGlobeNewsWire • 01/27/26
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured EnthusiasmSeeking Alpha • 01/13/26
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025GlobeNewsWire • 12/08/25
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewsWire • 11/24/25
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business UpdateGlobeNewsWire • 11/06/25
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)GlobeNewsWire • 07/29/25
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low OpportunitySeeking Alpha • 06/27/25
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRCGlobeNewsWire • 06/17/25
Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025GlobeNewsWire • 06/02/25
Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 05/14/25
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business UpdateGlobeNewsWire • 05/08/25